Affiliation:
1. Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki 852-8501, Japan
Abstract
ABSTRACT
In vitro and in vivo efficacies of NS-718, a lipid nanosphere-encapsulated amphotericin B (AMPH-B), have been studied. Of the tested AMPH-B formulations, NS-718 had the lowest MIC for
Cryptococcus neoformans
. In a murine model, low-dose therapy (0.8 mg/kg of body weight) with NS-718 showed higher efficacy than that with AmBisome. High-dose therapy (2.0 mg/kg) with NS-718 was much more effective than those with Fungizone and AmBisome. In mice treated with a high dose of NS-718, only a few yeast cells had grown in lung by 7 days after inoculation. A pharmacokinetic study showed higher concentrations of AMPH-B in lung following administration of NS-718 than after administration of AmBisome. Our results indicated that NS-718, a new AMPH-B formulation, is a promising antifungal agent for treatment of pulmonary cryptococcosis and could be the most effective antifungal agent against
C. neoformans
infections.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference19 articles.
1. Carrier effects on biological activity of amphotericin B
2. Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles
3. Phospholipase activity in Cryptococcus neoformans: a new virulence factor?;Chen S. C. A.;J. Infect. Dis.,1997
4. Poly(ɛ-caprolacton) nanoparticles as an alternative way to reduce amphotericin B toxicity.;Espuelas M. S.;Int. J. Pharm.,1997
5. Fukui
H.
Koike
T.
Saheki
A.
Sonoke
S.
Yoshikawa
H.
Sasaki
H.
Tomii
Y.
Seki
J.
A novel antifungal drug delivery system: lipid nano-sphere incorporating amphotericin B (LNS-AmB) abstr. 5026
Proceedings of the 23rd International Symposium on Controlled Release of Bioactive Materials Kyoto Japan
1996
655
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献